Table 2.
Results of primary outcomes by gestational age subgroup[33]
| Trial |
N |
Eligible (GA wks) |
DEATH or CP |
CP |
DEATH |
|---|---|---|---|---|---|
| RR, 95% CI | RR, 95% CI | RR, 95% CI | |||
| MagNetǂ [43] |
59 |
>24 to <34 |
4.83, 0.60 to 38.90 |
6.77, 0.37 to 125.65 |
1.93, 0.19 to 20.18 |
| Marret[46] |
688 |
viable to <33 |
0.80, 0.58 to 1.10 |
0.70, 0.41 to 1.19 |
0.85, 0.55 to 1.32 |
| Rouse[44] |
2444 |
24 to <32 |
0.90, 0.73 to 1.10 |
0.59, 0.40 to 0.85* |
1.13, 0.87 to 1.48 |
| Crowther[45] |
1255 |
<30 |
0.82, 0.66 to 1.02 |
0.85, 0.55 to 1.31 |
0.81, 0.62 to 1.05 |
| Overall | 4446 | viable to <34 | 0.85, 0.75 to 0.98* | 0.71, 0.55 to 0.91* | 0.95, 0.80 to 1.12 |
ǂNeuroprotective arm; CP cerebral palsy; GA gestational age; * statistically significant.